FIRST-IN-MAN STUDY OF 4SC-202, A NOVEL ORAL HDAC INHIBITOR IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES; (TOPAS STUDY)

被引：0

作者：

von Tresckow, B. ^{[1
]}

Goebeler, M. E. ^{[2
]}

Sayehli, C. ^{[2
]}

Gundermann, S. ^{[2
]}

Eichenauer, D. ^{[1
]}

Aulitzky, W. ^{[3
]}

Bacchus, L. ^{[3
]}

Igel, S. ^{[4
]}

Schwab, M. ^{[4
]}

Sasse, S. ^{[1
]}

Hauns, B. ^{[5
]}

Mais, A. ^{[5
]}

Hentsch, B. ^{[5
]}

Kohlhof, H. ^{[5
]}

Krauss, R. ^{[5
]}

Krauss, B. ^{[5
]}

Baumgartner, R. ^{[5
]}

Vitt, D. ^{[5
]}

Engert, A. ^{[1
]}

机构：

[1] Univ Hosp Cologne, Cologne, Germany

[2] Univ Hosp Wuerzburg, Wurzburg, Germany

[3] Robert Bosch Krankenhaus, Stuttgart, Germany

[4] Dr Margarte Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[5] 4SC AG, Planegg Martinsried, Germany

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PB1858

引用

页码：711 / 711

页数：1

共 50 条

[1] First-in-human study of 4SC-202, a novel oral HDAC inhibitor in advanced hematologic malignancies (TOPAS study).
von Tresckow, Bastian
Gundermann, Stefan
Eichenauer, Dennis A.
Aulitzky, Walter Erich
Goebeler, Mariele
Sayehli, Cyrus
Bacchus, Liza
Hauns, Bernhard
Mais, Anna
Hentsch, Bernd
Kohihof, Hella
Krauss, Rolf
Krauss, Babett
Baumgartner, Roland
Vitt, Daniel
Engert, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[2] Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies
von Tresckow, Bastian
Sayehli, Cyrus
Aulitzky, Walter E.
Goebeler, Maria-Elisabeth
Schwab, Matthias
Braz, Eunice
Krauss, Babett
Krauss, Rolf
Hermann, Frank
Bartz, Rene
Engert, Andreas
EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (02) : 163 - 173
[3] Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor
Henning, S. W.
Doblhofer, R.
Kohlhof, H.
Jankowsky, R.
Maier, T.
Beckers, T.
Schmidt, M.
Hentsch, B.
EJC SUPPLEMENTS, 2010, 8 (07): : 61 - 61
[4] Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
Maria Pinkerneil
Michèle J. Hoffmann
Hella Kohlhof
Wolfgang A. Schulz
Günter Niegisch
Targeted Oncology, 2016, 11 : 783 - 798
[5] Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
Pinkerneil, Maria
Hoffmann, Michele J.
Kohlhof, Hella
Schulz, Wolfgang A.
Niegisch, Guenter
TARGETED ONCOLOGY, 2016, 11 (06) : 783 - 798
[6] Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells
Huang Zhijun
Wang Shusheng
Min Han
Li Jianping
Qin Li-sen
Li Dechun
TUMOR BIOLOGY, 2016, 37 (08) : 10257 - 10267
[7] First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies
Ang, J. E.
Hauns, B.
Mais, A.
Parker, A.
Lal, R.
Olmos, D.
Mollenhauer, M.
Walz, A.
de Bono, J. S.
EJC SUPPLEMENTS, 2008, 6 (12): : 123 - 124
[8] FIRST-IN-MAN STUDY OF E-3810, A NOVEL VEGFR AND FGFR INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
Soria, J. C.
Dienstmann, R.
de Braud, F.
Cereda, R.
Bahleda, R.
Hollebecque, A.
Tabernero, J.
Delmonte, A.
Dromain, C.
Lassau, N.
Farace, F.
Zucchetti, M.
Marsoni, S.
Camboni, M. G.
ANNALS OF ONCOLOGY, 2012, 23 : 16 - 17
[9] First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors
Soria, J. C.
De Braud, F.
Cereda, R.
Bahleda, R.
Delmonte, A.
Angevin, E.
Varga, A.
Noberasco, C.
Dall'O', E.
Lassau, N.
Dromain, C.
Bellomi, M.
Farace, F.
Bertolini, F.
Zucchetti, M.
Marsoni, S.
Camboni, M. G.
ANNALS OF ONCOLOGY, 2011, 22 : 40 - 40
[10] First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.
Soria, J.
De Braud, F. G.
Cereda, R.
Bahleda, R.
Delmonte, A.
Angevin, E.
Varga, A.
Noberasco, C.
Dall'O, E.
Lassau, N.
Dromain, C.
Bellomi, M.
Farace, F.
Bertolini, F.
Zucchetti, M.
Marsoni, S.
Camboni, M. G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →